Drug Combination Details
| General Information of the Combination (ID: C12588) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | MG132 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Mantle cell lymphoma
[ICD-11: 2A85]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BNIP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | ||
| Raji | CVCL_0511 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| Experimental
Result(s) |
Synergism between ATO and MG132 was attained in Raji cells by disruption of the perinuclear mitochondrial cluster, blockage of selective autophagy of mitochondria (mitophagy) by VCR, increased mitochondrial mass, and upregulation of BNIP3 by VPA. | |||||
